LLY

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About Lilly(Eli) & Co

Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. It was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today it remains true to that mission in all its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
CEO
David Ricks
Employees
2020
Headquarters

Lilly Corporate Ctr
Indianapolis, Indiana 46285-0001
Phone: 13172762000
www.lilly.com

News

This Analyst Sees Potential Downside In Eli Lilly, Adjusts Model For Acquired IPR&D Charges
Jul 15, 2024 17:13pm

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co (NYSE: LLY ) and maintained a price target of $885. The company is slated to report its second-quarter FY24 earnings on August 8. The analyst highlighted that Eli Lilly’s GAAP and non-GAAP financial results for 2Q24 will include acquired IPR&D charges of ~$154 million on a pre-tax basis, representing a charge of ~$0.14 to both GAAP and non-GAAP earnings per share. The following are some of the points the analyst lists that are important for the company’s growth in the coming days. The analyst expects U.S. approval for Lebrikizumab to treat atopic dermatitis in 2H24E. Also Read : Full story available on Benzinga.com


Source:Benzinga
Jim Cramer: Eli Lilly(LLY) on Path to $1 Trillion Market Cap as Alzheimer’s Drug Can be a ‘Blockbuster’
Jul 15, 2024 12:20pm

We recently published a list of Jim Cramer Says You Should Buy These 10 Stocks. Since Eli Lilly & Co (NYSE:LLY) ranks 3rd on the list, it deserves a deeper look. Jim Cramer last week talked about the decline of tech stocks after the latest CPI report, saying investors “abandoned” tech stocks like “rats from the sinking […]


Source:Insider Monkey
3 Stocks for Patient Investors Looking to Build Generational Wealth
Jul 14, 2024 19:00pm

The best way to get rich is not through get-rich quick schemes — slow and steady wins the race. It is not something to achieve in a single quarter or even a year. You create financial freedom that you can pass on to your children and grandchildren over a lifetime. The best generational wealth stocks are those that pay dividends. Income-generating stocks have a long history of outperforming not only non-dividend-paying stocks but other asset classes as well. A Deutsche Bank study showed that over the past 100 years, equities beat out gold by 5.6% per year, housing prices by 6.6%, treasuries by 6.8% and oil by 8.4% per year. Over short periods of time one asset class or another may outperform stocks, but the long-term results prove that if you want to accumulate large amounts of wealth, investing in stocks is the way to go. And dividend stocks are the best-performing stocks. Several years ago, the asset managers at JPMorgan found that stocks initiating a dividend and then raising their payouts over a 40-year period between 1972 and 2012 returned an average of 9.5% annually, versus just 1.6% non-dividend-paying stocks.


Source:InvestorPlace
Is Eli Lilly a Good Dividend Stock to Buy Now?
Jul 14, 2024 10:31am

A leading anti-obesity treatment plus a new Alzheimer''s drug could drive profits through the roof.


Source:The Motley Fool
This 1 Piece of Bad News for Novo Nordisk Is Good News for Eli Lilly Stock
Jul 14, 2024 09:20am

A new study raises important implications regarding the competitive balance between these two companies.


Source:The Motley Fool
Should You Buy Eli Lilly Stock After Another Major Win?
Jul 12, 2024 10:13am

It was a buy even before this development.


Source:The Motley Fool
The 3 Most Undervalued Biotech Stocks to Buy in July 2024
Jul 12, 2024 10:08am

There’s always a strong case for undervalued biotech stocks . For one, the industry is only expected to grow. In fact, according to Grand View Research , biotech could be worth about $3.88 trillion by 2030. After all, there’s always going to be a need for biotech. Fueling even more upside is artificial intelligence, which may be able to create new drugs that can treat untreatable issues. There’s even newer innovation, demand for better treatment, pharmaceutical companies strengthening pipelines, gene editing and an unstoppable obesity treatment boom showing no signs of cooling. We’re even seeing a resurgence of M&A activity, with Eli Lilly (NYSE: LLY ) buying Morphic Holding for $3.2 billion. In short, biotech is an exciting sector with great upside potential moving forward. Even better, at times, we’re offered even more opportunity when we uncover severely undervalued biotech stocks, such as: Viking Therapeutics (VKTX) Source: shutterstock.com/Romix Image Every time I mention biotech opportunities, Viking Therapeutics (NASDAQ: VKTX ) leads the list.


Source:InvestorPlace
This weight loss stock is the best alternative to Eli Lilly, Novo - SA Sentiment
Jul 12, 2024 08:12am

No summary available.


Source:Seeking Alpha
Neuroendocrine Tumors Pipeline 2024 | Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene
Jul 11, 2024 18:50pm

DelveInsight''s, "Neuroendocrine Tumors Pipeline Insight 2024" report provides comprehensive insights about 115+ companies and 130+ pipeline drugs in Neuroendocrine Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuroendocrine Tumors


Source:OpenPR